Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Heidelberg Pharma AG

http://heidelberg-pharma.com/en/

Latest From Heidelberg Pharma AG

CDER Opposes Covis’ Bid To Steer Focus Away From Makena's Failed Confirmatory Trial

The company offered to stipulate that findings from the PROLONG trial do not verify clinical benefit of the preterm birth prevention drug; the US FDA’s drugs center opposed a stipulation, saying failure of a confirmatory trial to verify clinical benefit is an independent ground for withdrawing accelerated approval and an advisory committee should vote on the question.

Post Market Regulation & Studies Review Pathway

ALS Drugs: Second US FDA Meeting On AMX0035 Gives Amylyx A Chance To Capitalize On Recent Events

Company is coming into its second panel meeting with new data analyses from the CENTAUR trial, advisory committee experience under its belt, and a recent Health Canada approval. In an interview with the Pink Sheet, co-CEOs Cohen and Klee highlight clinical outcomes data with AMX0035 and say they are not too worried about the lack of effect on neurofilament biomarker.

Advisory Committees Drug Review

Who’s Hired? Teva Gets New Leadership In Canada

Teva has appointed a new general manager in Canada following the departure of Christine Poulin to Covis Pharma. At the same time, Amneal’s associate general counsel, Meredith Cook, has taken up a role at ANI Pharmaceuticals, while Alvotech has appointed several new directors to its board as part of its transition to being a publicly-listed company.

Executive Changes Leadership

Agios Recruits Rare Disease Leader Brian Goff As CEO To Execute Commercial Transition

Leadership change comes after CEO Jackie Fouse, who will serve as board chair, oversaw the sale of Agios' cancer portfolio, a reorganization and a shift in therapeutic focus to rare diseases.

Leadership Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Heidelberg Pharma Research GmbH
    • Wilex AG
UsernamePublicRestriction

Register